Qiming Venture Partners
- Company typePrivate
- Founded2006
- HeadquartersShanghai, China
- Headcount51–100
- GTM typeB2B
- OfferingServices
Qiming Venture Partners firmographics
Firmographics- Name
- Qiming Venture Partners
- Legal name
- Qiming Weichuang Venture Capital Management (Beijing) Co., Ltd. (启明维创创业投资管理（北京）有限公司)
- Website
- http://www.qimingvc.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Qiming Venture Partners industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Qiming Venture Partners is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Qiming Venture Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Management Fees: Qiming Venture Partners generates revenue primarily through management fees on its 11 USD funds and 7 RMB funds, totaling $9.5 billion in AUM (as of August 2024). This represents a standard asset management fee structure.
- Carried Interest from Exits: Qiming generates carried interest through 70+ IPOs and 140+ M&A and other exits. Portfolio exits span US (NYSE, NASDAQ), Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, including companies such as Xiaomi, Meituan, Bilibili, Zhihu, and more.
Go-to-market motion3 records
Qiming Venture Partners product offering
Product offeringCore offering
Qiming Venture Partners is a private venture capital firm that raises and manages investment funds (11 USD funds and 7 RMB funds totaling US$9.5 billion in AUM as of August 2024) and deploys that capital into early- and growth-stage startups in Technology and Healthcare sectors. The firm provides portfolio companies with capital, strategic guidance, industry resources, and post-investment ecosystem support. It generates returns through management fees and carried interest from exits via IPOs (NYSE, NASDAQ, HKEX, SSE, SZSE) and M&A transactions.
Product overview
Qiming Venture Partners (启明创投) operates a single integrated venture capital platform rather than a software product portfolio: it is a single firm-wide investment business composed of multiple fund vehicles (11 USD funds and 7 RMB funds) that deploy capital across two main investment verticals — Technology and Healthcare Innovation. The Technology vertical covers TMT, AI, robotics, semiconductors, enterprise services, blockchain, mobility, and consumer internet; the Healthcare Innovation vertical covers innovative drugs, diagnostics, medical devices, medical services, and AI/digital health. Layered on top of the core fund products are add-on services — a portfolio value-add / ecosystem program, the S2S China Symposium co-hosted with RA Capital Management (first edition scheduled October 15, 2026 in Hangzhou), the Healthcare PhD Summer Internship Program (2026 cohort announced May 2026), and ESG initiatives such as the China Rural Revitalization Entrepreneurs Support Program. As of August 2024 the firm managed US$9.5 billion in AUM, had invested in 580+ portfolio companies, recorded 70+ IPOs and 140+ M&A or other exits, and counted among its investments Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI), Zhihu (NYSE:ZH), Roborock (688169.SH), Hesai (NASDAQ:HSAI), UBTech (09880.HK), WeRide (NASDAQ:WRD), Hyperstrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Z.ai/Zhipu AI (02513.HK), Tigermed (300347.SZ), ZaiLab (NASDAQ:ZLAB), and CanSino Bio (688185.SH).
Differentiator
Problem solved
Functional benefit
Products and services
- USD Funds (11 funds)
- RMB Funds (7 funds)
- Technology Sector Investing
- Healthcare Innovation Investing
- Qiming Portfolio Value-Add / Ecosystem Services
Quantifiable outcome
- 70+ portfolio company IPOs and 140+ M&A or other exits
- +4 more outcomes
Companies that use Qiming Venture Partners
Customer profileNamed customers23 records
Ideal customer profiles3 records
Qiming Venture Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Qiming Venture Partners partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship.
- RA Capital ManagementflagshipCo-host of the inaugural S2S China Symposium, scheduled for October 15, 2026, in Hangzhou, China. The event aims to connect top Chinese scientists with major biotech investors and accelerate biotech innovation and commercialization in China.
- XiaomiflagshipLong-term strategic relationship; Qiming has trusted and heavily invested in the Mi Team from Xiaomi to Xiaomi Ecosystem. Lei Jun serves as Founder, Chairman & CEO. Quote from Lei Jun: 'From Xiaomi to Xiaomi Ecosystem, Qiming has always been trusting and heavily investing in the Mi Team.'
- MedtronicflagshipStrategic investment partnership where Qiming participated as an existing investor in Pulnovo Medical's $100M strategic financing led by Medtronic in April 2026. Pulnovo and Medtronic signed a commercial agreement for global commercialization of the PADN System.
- Hong Kong Stock ExchangeflagshipQiming's portfolio companies have listed extensively on the Hong Kong Stock Exchange, including LongBio Pharma (June 2026), Viewtrix (May 2026), Axera (Feb 2026), Biren Technology (Jan 2026), Z.ai (Jan 2026), Yunji Technology (Oct 2025), and Insilico Medicine (Dec 2025).
- AstraZenecaflagshipAstraZeneca participated as existing shareholder in Syneron Bio's $150M Series B financing, co-led by Qiming in March 2026. AstraZeneca had previously signed a deal with Syneron Bio worth $75M upfront plus up to $3.4 billion in potential milestones.
- TigermedflagshipLong-term portfolio company; Tigermed (300347.SZ, 03347.HK) is a leading clinical trial CRO. Qiming has supported Tigermed from early stages, with founder Ye Xiaoping noting: 'We have created a model for the cooperation between entrepreneurs and venture capitalists. We support each other along the way.'
- Tencent (as former employer)flagshipConnection through Video Rebirth founder Liu Wei, who previously led development of Tencent's flagship AI model.
- Z.ai (Zhipu AI)flagshipQiming co-led Z.ai's Series B1 funding in early 2022, validating China's foundational AI innovation path. Z.ai listed on HKEX on January 8, 2026, becoming the world's first listed LLM company.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Qiming Venture Partners competitors and assessment
Company assessmentDirect peers
- HongShan (formerly Sequoia China): Sequoia China's spin-out is the closest direct peer to Qiming — a leading China VC with comparable dual focus on TMT and healthcare, similar AUM scale, similar Series A/B concentration, and overlapping LP base. Frequent co-investor in deals like XunTu Technology.
- IDG Capital: One of the longest-established foreign-affiliated China VCs covering TMT, healthcare, and consumer at early and growth stages. Directly comparable investment mandate, fund structure, and target portfolio to Qiming.
- Matrixpartners China: US-pedigree early-stage China VC with comparable focus on technology and healthcare startups. Comparable Series A/B entry point and similar LP profile makes it one of Qiming's most direct competitors.
- Legend Capital: Beijing-headquartered early- and growth-stage VC with comparable dual focus on technology and healthcare in China. Similar fund size profile and similar sector mandate to Qiming.
- Source Code Capital: China-focused early-stage VC with TMT and consumer emphasis. Comparable Series A/B entry and overlapping target founder base with Qiming in Chinese internet/enterprise software.
- Northern Light Venture Capital: China-domiciled early- and growth-stage VC with strong TMT focus. Comparable Series A/B entry stage and overlapping portfolio characteristics with Qiming's technology investments.
- Shunwei Capital: China-focused VC with deep TMT and AI exposure. Comparable early-stage entry and increasingly comparable AI thesis to Qiming, especially in AI/consumer-internet investments.
- 5Y Capital (formerly Morningside Venture Capital): Long-established China VC with TMT and healthcare focus. Comparable fund vintage, comparable Series A/B entry stage, and overlapping LP relationships make it a structural peer to Qiming.
Broad incumbents
- Hillhouse Capital: Broader Asia-focused investment platform with TMT and healthcare exposure across public and private markets. Larger and more diversified than Qiming, but overlaps significantly on growth-stage technology and biotech deals (co-investor with Qiming in XunTu Technology).
- CDH Investments: Major Chinese alternative asset manager with both growth equity and buyout strategies. Overlaps with Qiming on healthcare and technology growth-stage deals; broader mandate and larger AUM put it in the incumbent category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights8 records
Customer concentration
Qiming Venture Partners social profiles
Digital presenceQiming Venture Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qiming Venture Partners leadership team
Management profileNumber of profiles
Profiles6 records
Qiming Venture Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
Qiming Venture Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qiming Venture Partners M&A and investment
M&A and investmentM&A
Investments1171 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qiming Venture Partners
What does Qiming Venture Partners do?
Qiming Venture Partners is a private venture capital firm that raises and manages investment funds (11 USD funds and 7 RMB funds totaling US$9.5 billion in AUM as of August 2024) and deploys that capital into early- and growth-stage startups in Technology and Healthcare sectors. The firm provides portfolio companies with capital, strategic guidance, industry resources, and post-investment ecosystem support. It generates returns through management fees and carried interest from exits via IPOs (NYSE, NASDAQ, HKEX, SSE, SZSE) and M&A transactions.
Is Qiming Venture Partners a public or private company?
Qiming Venture Partners is a private company. It is classified as management employee owned and is currently operating.
When was Qiming Venture Partners founded?
Qiming Venture Partners was founded in 2006. It employs 51 to 100 people.
Where is Qiming Venture Partners based?
Qiming Venture Partners is headquartered in Shanghai, China, in the Asia region.
How does Qiming Venture Partners make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest from Exits.
Who are Qiming Venture Partners's main competitors?
Direct peers on record are HongShan (formerly Sequoia China), IDG Capital, Matrixpartners China, Legend Capital, Source Code Capital, Northern Light Venture Capital, Shunwei Capital and 5Y Capital (formerly Morningside Venture Capital). Broad incumbents are Hillhouse Capital and CDH Investments.
Does Qiming Venture Partners have an API?
No public API is recorded for Qiming Venture Partners.
What industry is Qiming Venture Partners in?
Qiming Venture Partners's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.